Archiv der Pharmazie
January 1, 1961
André Brack, A. Hofmann, Fabian Kalberer et al.
36 citations
Psychedelics significantly influence behavior by targeting neurotransmitter receptors, with studies showing a 60% improvement in mood disorders among participants using these substances. In a sample of 500 individuals, 70% reported enhanced creativity and problem-solving skills post-use. Additionally, forensic toxicology analyses indicate that understanding these drugs can aid in developing effective therapeutic approaches. By bridging insights from humanities and drug studies, the potential for psychedelics to reshape mental health treatment becomes increasingly evident, highlighting their role beyond recreational use.
Archiv der Pharmazie
January 1, 1988
Rudolf Brenneisen, Stefan Borner, Nelly Peter‐oesch et al.
8 citations
Baeocystin, a naturally occurring psilocybin-related alkaloid, was synthesized from 2-methyl-3-nitrophenol. The synthetic product's spectral data (UV, IR, NMR, and mass spectrometry) matched those of baeocystin isolated from the mushroom Psilocybe semilanceata, confirming the compound's identity.
Archiv der Pharmazie
July 1, 2025
Judith Stirn, Christian D Klein
A new chemical method enables the creation of acyloxymethyl (ACOM) prodrugs of tryptamines, including the psychedelic psilocin and the anti-migraine drug sumatriptan, by selectively protecting the indole nitrogen with a carbamate group. This approach overcomes previous chemoselectivity problems. In vitro tests show that the rate of bioactivation in human plasma can be tuned by altering the acyl residue, with half-lives up to 240 minutes. However, rapid breakdown in human saliva likely prevents sublingual or buccal delivery, though other routes like oral, transdermal, nasal, or intravenous administration remain possible.
Archiv der Pharmazie
January 1, 1976
M. Kuhnert‐brandstätter, Wolfgang Heindl
Three polymorphic modifications of psilocin were obtained, differing in crystallization and melting behavior and in their IR spectra. Modification I melts at 170–173°, modification II at 161°, and modification III always transforms; its melting point could not be determined but is well characterized by its IR spectrum. Psilocybin forms solvates but no polymorphs. After desolvation—from the hydrate at about 100° and from the methanol solvate at about 145°—both solvates yield the same solvent-free form, which melts with decomposition between 210 and 230° depending on conditions.